Co-Founder and CEO Daniel Fischer describes how Tevard is harnessing tRNA for drug development against muscular dystrophies, cardiomyopathies, and epilepsies. The company could run basket trials and possibly earn flexible labels because these tRNAs are targeting a class of mutations rather than specific genes. Coverage brought to you by

Co-Founder & CEO Ken Greenberg describes the idea around and advantages of this approach, including no limitation on cargo size. He describes how it would work for DMD, and what other conditions and uses they are thinking of next. Coverage brought to you by

He describes the work he is involved in with ARTAN Bio, which has a tRNA suppressors approach to diseases of aging and logevity. Plus, a unique crypto financing angle to this story. Coverage brought to you by

Erik Wiklund describes the advantages of circular RNA, and the progress the company has been making since last year's ASGCT. With partnerships and additional funding in hand since then, the company is accelerating its work in multiple dimensions. Coverage brought to you by

CEO Jeff Walsh describes the concept of epigenetic editing and why the company chose Hepatitis B, and walks us through the dose escalation schedule that the trial is going through. Plus, work on a virus-like particle delivery method that the company envisions for non-liver delivery. Coverage brought to you by

CEO Rodolphe Clerval describes the platform, which they can partner using a company's existing AAV assets or with Coave's new OneAAV universal capsid. Plus, why he thinks Coave's wet AMD program, which will be administered at the point of care, could be best in class. Coverage brought to you by

Co-Founder and CEO Simon Xi discusses the company's Rswitch platform, which was the basis of an ASGCT presentation showing that the company could modulate levels of Frataxin in a Friedreich’s Ataxia mouse model. Coverage brought to you by

She describes how the first trials will target glioma, a type of brain cancer, and Siren has also done work to show that the approach could be a universal therapy that may have utility against numerous cancers. Plus, how Siren did a unique crowdfunded $5 million fundraise. Coverage brought to you by

Co-Founder & CEO Avencia Sánchez-Mejías describes the science of how they achieve this. At ASGCT, the company is presenting the second generation of FiCAT, and offers examples of introducing 3 or 4 genes. Coverage brought to you by

Co-Founder & CEO Kartik Ramamoorthi walks us through the data and describes Encoded's platform, which is designed to get to the right cells specifically within the brain to treat this and other conditions. Coverage brought to you by

Co-Founder Lex Johnson walks us through the science, which is nearing the clinic with partner Bristol. Plus, an explanation of the ASGCT presentation on their cytokine and why they believe it is important. Coverage brought to you by

CSO Robert Bell describes the advantages of RNA exon editing he sees over DNA editing, and walks us through the safety data. With that in hand, which was in adult patients, the company is moving forward in pediatric patients. Coverage brought to you by

CEO Amber Salzman walks us through the science, which allows the company to dial up or dial down genes of interest rather than making a cut into the DNA. They have dosed patients with FSHD, a type of muscular dystrophy, and have ASGCT presentations looking at other indications like Friedreich's ataxia, a type of Alzheimer's, and DMD. Coverage brought to you by

He highlights key issues around capsids and immunogenicity, in vivo engineering, using cell therapies for autoimmune, and, of course, how AI is affecting this science. Coverage brought to you by

CEO Devyn Smith describes the significance of today's news. Arbor is thinking about numerous CNS conditions, including ALS. Plus, he shares an update on their liver mediated disease programs with partner Chiesi. Coverage brought to you by

He shares advice for what areas of science PhDs might pursue in industry, how to success (get stuff done) and validating science.

Co-Founder & CEO Natalie Mount discusses the raise, and explains why she believes gamma delta T-cell engagers have advantages over CD3s. After presenting preclinical data at the recent AACR annual meeting, the lead EGFR program is preparing to go into the clinic.